市場調查報告書
商品編碼
925267

T細胞急性淋巴性白血病:2020年∼2025年

T-cell Acute Lymphoblastic Leukemia Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

T細胞急性淋巴芽球性白血病市場成長的主要原因,是全球該疾病的盛行率上升。美國臨床腫瘤學會(ASCO)的研究,T細胞性急性淋巴芽球性白血病治療估計是全急性淋巴芽球性白血病的15%∼20%。

本報告提供T細胞急性淋巴性白血病的世界市場調查,市場概要,各類型、終端用戶、地區的市場趨勢,市場規模的變化與預測,市場促進、阻礙因素以及市場機會分析,競爭情形,主要企業的簡介等全面性資訊 。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 成長要素
  • 阻礙因素
  • 波特的五力分析
    • 新加入廠商的威脅
    • 消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業內的競爭

第5章 市場區隔

  • 各治療類型
    • 化療
    • 放射治療
    • 幹細胞移植
    • 其他
  • 各終端用戶
    • 醫院
    • 癌症、放射治療中心
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Bristol Myer Squibb Company
    • Celegene Corporation
    • Kyowa Kirin Co., Ltd.
    • Erytech Pharma
    • F. Hoffmann-La Roche Ltd
    • Genmab AS
    • GlaxoSmithKline
    • Novartis AG
    • Pfizer Inc.
    • Spectrum Pharmaceuticals

第7章 市場機會及未來趨勢

目錄
Product Code: 67785

Key Highlights

  • Major factor that is responsible for the growth of T-cell acute lymphoblastic leukaemia market is the rising prevalence of T-cell acute lymphoblastic leukaemia globally.
  • T-cell Acute Lymphoblastic Leukemia Treatment estimated for 15% to 20% of all acute lymphoblastic leukemia by study of the American Society of Clinical Oncology (ASCO). The number of new cases being recorded each year is around 1.7 per 100,000 men and women per year. It has been estimated by the American Cancer Institute that, in 2019, there were around 5,930 new cases of ALL i.e. 3,280 in males and 2,650 in females.
  • Additionally, growing research and development expenditure on cancer therapeutics, increasing healthcare expenditure and innovations in novel drug development are also propelling the growth of the T-cell acute lymphoblastic leukaemia market globally.
  • However, stringent regulations for the approval of T-ALL drugs, high cost of the treatment and adverse effects associated with therapies are the factors that may hamper the growth of the market.

Key Market Trends

Chemotherapy dominate the Global T-cell Acute Lymphoblastic Leukemia Treatment Market

  • The American Cancer Association stated that chemotherapy is the main treatment for the people suffering from acute lymphoblastic leukemia (ALL), and it has three phases, such as remission, consolidation, and maintenance. Chemotherapy drugs are the cell-killing therapeutics. These drugs kill the cancer cells and stop them from dividing.
  • Chemotherapy is normally given as a combination of drugs and for T-ALL, will always include steroids. T-ALL cells is found in the cerebro spinal fluid (CSF) so chemotherapy for the T-ALL includes injections into CSF. This is called intrathecal chemotherapy. This is more common in T-ALL than in other forms of ALL.

North America Dominates the Global T-cell Acute Lymphoblastic Leukemia Treatment Market

North America holds a significant market share in the global T-ALL Treatment market and is expected to withstand its position over the forecast period. The diagnosis and prevalence rates of T-ALL is growing rapidly in the region. Moreover, favorable government policies, well-established healthcare infrastructure, and the presence of multinational companies make this region dominant in this market.

Competitive Landscape

Currently, many private companies are focusing on the development and introduction of novel therapeutics. Additionally, extensive research and development activities are being initiated by most of the market players, government organizations and academic research institutes. Some of the key innovations in the market are: In 2017, Researchers at the Spanish National Cancer Research Centre (CNIO) have discovered a genetic alteration in specific gene, known as Capicua, has been inactivated and that is directly involved in at least 10% of cases of one of the most common cancers in children, T-cell acute lymphoblastic leukemia.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of T-cell Acute Lymphoblastic Leukemia Market
    • 4.2.2 Growing Research and Development Expenditure on Cancer Therapeutics
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Scenario for the Drug Approvals
    • 4.3.2 High Cost Asscoiated with the Treatment
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type of Therapy
    • 5.1.1 Chemotherapy
    • 5.1.2 Radiation therapy
    • 5.1.3 Stem cell transplant
    • 5.1.4 Others
  • 5.2 By End User
    • 5.2.1 Hospitals
    • 5.2.2 Cancer and Radiation Therapy Centers
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Bristol Myer Squibb Company
    • 6.1.2 Celegene Corporation
    • 6.1.3 Kyowa Kirin Co., Ltd.
    • 6.1.4 Erytech Pharma
    • 6.1.5 F. Hoffmann-La Roche Ltd
    • 6.1.6 Genmab AS
    • 6.1.7 GlaxoSmithKline
    • 6.1.8 Novartis AG
    • 6.1.9 Pfizer Inc.
    • 6.1.10 Spectrum Pharmaceuticals

7 MARKET OPPORTUNITIES AND FUTURE TRENDS